{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T06:59:01Z","timestamp":1764053941101},"reference-count":22,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,4]]},"DOI":"10.7759\/cureus.70859","type":"journal-article","created":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T22:40:41Z","timestamp":1728081641000},"source":"Crossref","is-referenced-by-count":1,"title":["Effectiveness of Resmetirom in Reducing Cholesterol Levels in Patients With Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis"],"prefix":"10.7759","author":[{"given":"Estifanos","family":"Bejitual","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Faisal","family":"Awais","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dhruvi","family":"Modi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ushna","family":"Gul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kinan","family":"Obeidat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Najeeha","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Daniyal","family":"Waheed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shamsha","family":"Hirani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Nonalcoholic fatty liver disease: clinical features and pathogenesis","volume":"2","author":"Basaranoglu M","year":"2006","unstructured":"Basaranoglu M, Neuschwander-Tetri BA. Nonalcoholic fatty liver disease: clinical features and pathogenesis. Gastroenterol Hepatol (N Y). 2006, 2:282-91.","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.04.015","article-title":"Mechanisms and disease consequences of nonalcoholic fatty liver disease","volume":"184","author":"Loomba R","year":"2021","unstructured":"Loomba R, Friedman SL, Shulman GI. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell. 2021, 184:2537-64. 10.1016\/j.cell.2021.04.015","journal-title":"Cell"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14322","article-title":"Nonalcoholic fatty liver disease as a metabolic disease in humans: a literature review","volume":"23","author":"Cariou B","year":"2021","unstructured":"Cariou B, Byrne CD, Loomba R, Sanyal AJ. Nonalcoholic fatty liver disease as a metabolic disease in humans: a literature review. Diabetes Obes Metab. 2021, 23:1069-83. 10.1111\/dom.14322","journal-title":"Diabetes Obes Metab"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.6799","article-title":"Increased levels of low-density lipoprotein cholesterol within the normal range as a risk factor for nonalcoholic fatty liver disease","volume":"7","author":"Sun DQ","year":"2016","unstructured":"Sun DQ, Liu WY, Wu SJ, et al.. Increased levels of low-density lipoprotein cholesterol within the normal range as a risk factor for nonalcoholic fatty liver disease. Oncotarget. 2016, 7:5728-37. 10.18632\/oncotarget.6799","journal-title":"Oncotarget"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s11901-020-00530-0","article-title":"Cardiovascular disease in nonalcoholic steatohepatitis: screening and management","volume":"19","author":"Shroff H","year":"2020","unstructured":"Shroff H, VanWagner LB. Cardiovascular disease in nonalcoholic steatohepatitis: screening and management. Curr Hepatol Rep. 2020, 19:315-26. 10.1007\/s11901-020-00530-0","journal-title":"Curr Hepatol Rep"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-022-01028-4","article-title":"Management of dyslipidemia in patients with non-alcoholic fatty liver disease","volume":"24","author":"Martin A","year":"2022","unstructured":"Martin A, Lang S, Goeser T, Demir M, Steffen HM, Kasper P. Management of dyslipidemia in patients with non-alcoholic fatty liver disease. Curr Atheroscler Rep. 2022, 24:533-46. 10.1007\/s11883-022-01028-4","journal-title":"Curr Atheroscler Rep"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/nu15081954","article-title":"A review of the effects of fucoxanthin on NAFLD","volume":"15","author":"Sayuti NH","year":"2023","unstructured":"Sayuti NH, Muhammad Nawawi KN, Goon JA, Mokhtar NM, Makpol S, Tan JK. A review of the effects of fucoxanthin on NAFLD. Nutrients. 2023, 15:1954. 10.3390\/nu15081954","journal-title":"Nutrients"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.17925\/EE.2023.19.1.60","article-title":"Resmetirom: an orally administered, smallmolecule, liver-directed, \u03b2-selective THR agonist for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis","volume":"19","author":"Karim G","year":"2023","unstructured":"Karim G, Bansal MB. Resmetirom: an orally administered, smallmolecule, liver-directed, \u03b2-selective THR agonist for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. touchREV Endocrinol. 2023, 19:60-70. 10.17925\/EE.2023.19.1.60","journal-title":"touchREV Endocrinol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2024.155835","article-title":"Resmetirom, the first approved drug for the management of metabolic dysfunction-associated steatohepatitis: trials, opportunities, and challenges","volume":"154","author":"Kokkorakis M","year":"2024","unstructured":"Kokkorakis M, Boutari C, Hill MA, Kotsis V, Loomba R, Sanyal AJ, Mantzoros CS. Resmetirom, the first approved drug for the management of metabolic dysfunction-associated steatohepatitis: trials, opportunities, and challenges. Metabolism. 2024, 154:155835. 10.1016\/j.metabol.2024.155835","journal-title":"Metabolism"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2024.07.003","article-title":"Expert panel recommendations: practical clinical applications for initiating and monitoring resmetirom in patients with MASH\/NASH and moderate to noncirrhotic advanced fibrosis","author":"Noureddin M","year":"2024","unstructured":"Noureddin M, Charlton MR, Harrison SA, et al.. Expert panel recommendations: practical clinical applications for initiating and monitoring resmetirom in patients with MASH\/NASH and moderate to noncirrhotic advanced fibrosis. Clin Gastroenterol Hepatol. 2024, 10.1016\/j.cgh.2024.07.003","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/jep.13159","article-title":"Comparison of four heterogeneity measures for meta-analysis","volume":"26","author":"Lin L","year":"2020","unstructured":"Lin L. Comparison of four heterogeneity measures for meta-analysis. J Eval Clin Pract. 2020, 26:376-84. 10.1111\/jep.13159","journal-title":"J Eval Clin Pract"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32517-6","article-title":"Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"394","author":"Harrison SA","year":"2019","unstructured":"Harrison SA, Bashir MR, Guy CD, et al.. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet. 2019, 394:2012-24. 10.1016\/S0140-6736(19)32517-6","journal-title":"The Lancet"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1657","article-title":"Effects of resmetirom on noninvasive endpoints in a 36\u2010week phase 2 active treatment extension study in patients with NASH","volume":"5","author":"Harrison SA","year":"2021","unstructured":"Harrison SA, Bashir M, Moussa SE, McCarty K, Pablo Frias J, Taub R, Alkhouri N. Effects of resmetirom on noninvasive endpoints in a 36\u2010week phase 2 active treatment extension study in patients with NASH. Hepatol Commun. 2021, 5:573-88. 10.1002\/hep4.1657","journal-title":"Hepatol Commun"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison SA","year":"2024","unstructured":"Harrison SA, Bedossa P, Guy CD, et al.. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N Engl J Med. 2024, 390:497-509. 10.1056\/NEJMoa2309000","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.04.043","article-title":"Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease","volume":"149","author":"Angulo P","year":"2015","unstructured":"Angulo P, Kleiner DE, Dam-Larsen S, et al.. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015, 149:389-97.e10. 10.1053\/j.gastro.2015.04.043","journal-title":"Gastroenterology"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1177\/0004563220969150","article-title":"Clinical and laboratory aspects of 3,3',5'-triiodothyronine (reverse T3)","volume":"58","author":"Halsall DJ","year":"2021","unstructured":"Halsall DJ, Oddy S. Clinical and laboratory aspects of 3,3',5'-triiodothyronine (reverse T3). Ann Clin Biochem. 2021, 58:29-37. 10.1177\/0004563220969150","journal-title":"Ann Clin Biochem"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.00331","article-title":"Selective thyroid hormone receptor-beta (TR\u03b2) agonists: New perspectives for the treatment of metabolic and neurodegenerative disorders","volume":"7","author":"Saponaro F","year":"2020","unstructured":"Saponaro F, Sestito S, Runfola M, Rapposelli S, Chiellini G. Selective thyroid hormone receptor-beta (TR\u03b2) agonists: New perspectives for the treatment of metabolic and neurodegenerative disorders. Front Med (Lausanne). 2020, 7:331. 10.3389\/fmed.2020.00331","journal-title":"Front Med (Lausanne)"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2023-330596","article-title":"Thyroid hormone receptor-beta agonists: new MASLD therapies on the horizon","volume":"73","author":"Byrne CD","year":"2024","unstructured":"Byrne CD, Targher G, Tilg H. Thyroid hormone receptor-beta agonists: new MASLD therapies on the horizon. Gut. 2024, 73:573-81. 10.1136\/gutjnl-2023-330596","journal-title":"Gut"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcrp.2023.200197","article-title":"Lower low density lipoprotein cholesterol associates to higher mortality in non-diabetic heart failure patients","volume":"18","author":"Gouveia R","year":"2023","unstructured":"Gouveia R, Madureira S, Elias C, et al.. Lower low density lipoprotein cholesterol associates to higher mortality in non-diabetic heart failure patients. Int J Cardiol Cardiovasc Risk Prev. 2023, 18:200197. 10.1016\/j.ijcrp.2023.200197","journal-title":"Int J Cardiol Cardiovasc Risk Prev"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2023.102935","article-title":"Management of type 2 diabetes in patients with compensated liver cirrhosis: short of evidence, plenty of potential","volume":"18","author":"Arvanitakis K","year":"2024","unstructured":"Arvanitakis K, Koufakis T, Kalopitas G, Papadakos SP, Kotsa K, Germanidis G. Management of type 2 diabetes in patients with compensated liver cirrhosis: short of evidence, plenty of potential. Diabetes Metab Syndr. 2024, 18:102935. 10.1016\/j.dsx.2023.102935","journal-title":"Diabetes Metab Syndr"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-076388","article-title":"Association of non-alcoholic fatty liver disease with cardiovascular disease and all cause death in patients with type 2 diabetes mellitus: nationwide population based study","volume":"384","author":"Kim KS","year":"2024","unstructured":"Kim KS, Hong S, Han K, Park CY. Association of non-alcoholic fatty liver disease with cardiovascular disease and all cause death in patients with type 2 diabetes mellitus: nationwide population based study. BMJ. 2024, 384:e076388. 10.1136\/bmj-2023-076388","journal-title":"BMJ"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1002\/oby.21879","article-title":"Nonalcoholic steatohepatitis is associated with cardiac remodeling and dysfunction","volume":"25","author":"Simon TG","year":"2017","unstructured":"Simon TG, Bamira DG, Chung RT, Weiner RB, Corey KE. Nonalcoholic steatohepatitis is associated with cardiac remodeling and dysfunction. Obesity (Silver Spring). 2017, 25:1313-6. 10.1002\/oby.21879","journal-title":"Obesity (Silver Spring)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/299313-effectiveness-of-resmetirom-in-reducing-cholesterol-levels-in-patients-with-nonalcoholic-steatohepatitis-a-systematic-review-and-meta-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T22:40:43Z","timestamp":1728081643000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/299313-effectiveness-of-resmetirom-in-reducing-cholesterol-levels-in-patients-with-nonalcoholic-steatohepatitis-a-systematic-review-and-meta-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,4]]},"references-count":22,"URL":"https:\/\/doi.org\/10.7759\/cureus.70859","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10,4]]}}}